Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma

BACKGROUND: The current standard of care for pancreatic cancer is weekly gemcitabine administered for 3 of 4 weeks with a 1-week break between treatment cycles. Maximum tolerated dose (MTD)-driven regimens as such are often associated with toxicities. Recent studies demonstrated that frequent dosing...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Cham, K K Y, Baker, J H E, Takhar, K S, Flexman, J A, Wong, M Q, Owen, D A, Yung, A, Kozlowski, P, Reinsberg, S A, Chu, E M, Chang, C-W A, Buczkowski, A K, Chung, S W, Scudamore, C H, Minchinton, A I, Yapp, D T T, Ng, S S W
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2010
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2905290/
https://ncbi.nlm.nih.gov/pubmed/20531411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605727
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados